查看: 418|回复: 0

治疗重点 - 如何解决Car-T疗法中的复发难题?

发表于 2016-1-4 21:44:13 | 显示全部楼层 |阅读模式
治疗重点 - 如何解决Car-T疗法中的复发难题?
        Several companies’ CAR-T therapies have already produced impressive remission rates in leukaemia patients, but a high rate of relapses continues to cloud their long-term potential, especially considering the likely cost.
Several strategies have emerged to overcome this, one of which is Novartis ’s design of a CAR construct with a humanised antigen-binding region, the theory being that the commonly used murine CARs are being rejected by the immune system. But if this is the way forward it could leave Novartis ’s CTL019 – the industry‘s most-advanced CAR-T asset – and other murine constructs in a bind.
There is little data to go on at present, but one of the most hotly awaited presentations of the recent ASH meeting concerned the first data from a trial of six CTL019 -treated patients retreated with Novartis ’s new humanised, CD19 -targeting CAR, CTL119. Three of these went into complete remission, one of which was still ongoing at almost six months.
Dr Shannon Maude, of the Children's Hospital of Philadelphia, said it was particularly impressive that one of the remitting patients had had no response to the murine CTL019 . It is early days, but further positive data in a larger patient set would put Novartis in a quandary: should the group even bother filing CTL019 , or should it just switch to CTL119?
This might hit sentiment behind Novartis and the entire CAR-T space alike, given that the Swiss firm is the furthest advanced here, and it still hopes to submit CTL019 for approval next year. Switching to CTL119 would naturally imply a later filing.
Little is known about other players’ plans to develop humanised CARs; Kite has made a patent filing for one, while Juno refers to a bonus due to its R&D head, Mark Frohlich, on first patient dosing in a pivotal trial with a fully humanized CAR-T cell product.
CD19 -positive or antigen escape?
Of course such considerations relate to so-called CD19 -positive relapses – where patients’ leukaemia continues to express the CD19 antigen, with relapse due to waning CAR-T cells or loss of the CAR construct.
In the latest cut of Novartis ’s CTL019 data a highly impressive 93% of ALL patients went into complete remission after a month, though less impressively this rate was down to 30% by one year. At ASH the Children's Hospital of Philadelphia’s Dr Stephan Grupp said CD19 -positive relapse was responsible for a third of recurrences (ASH – CAR-T struggles to travel beyond leukaemia, December 8, 2015).
The remaining two thirds relapse because of loss of the CD19 antigen, and clearly require an entirely different retreatment approach. One strategy is to target a separate antigen, and fortunately in B-cell malignancies an alternative one seems to exist: CD22.
The leading project here is JCAR018 , an anti-CD22 CAR derived from work at the NIH that Juno bought from Opus Bio last year for about $120m. A first-in-human trial of JCAR018 featured at a separate ASH poster detailing a cohort of seven evaluable ALL patients, six of whom had been treated with an anti-CD19 CAR , and five of whom had had CD19 -negative relapse.
Complete remission was seen in two patients. It is early days here, too, and the best that can be said beyond initial efficacy hints is that there was no severe cytokine release syndrome, suggesting relative safety of JCAR018 , though most of the patients were given the lowest CAR-T cell dose.
Selection of antigens against which CAR-T therapies are being developed has tended to follow development of antibodies, and CD22 is no exception, but it is interesting that anti-CD22 MAbs, including MEDI-553 and IMTOX 22-97, have all failed in oncology, while’s epratuzumab failed in lupus.
Several antibody-drug conjugates are in development, as well as UCART22 , an allogeneic CAR-T therapy from Cellectis that also has a dCK gene knockout to confer fludarabine resistance.
At ASH the NCI’s Dr Daniel Lee said he was continuing to enrol CD19 -escaped patients into a CD22 CAR-T study, though all the data and IP arising from this will presumably belong not to the NCI’s CRADA partner Kite , but rather to Juno.
Dr Lee also cited a planned study of a bivalent CD19 -CD22 CAR, a highly unusual single CAR construct that was featured at an ASH poster. The NCI authors concluded that the order of the CD19 and CD22 binding domains, and the length of the linker, affected function, and despite some evidence of activity further optimisation is needed before this enters the clinic.
Persistence problems
When it comes to CD19 -positive relapses, developers of CAR-T therapies have to contend with a separate problem, namely the lack of persistence of the CAR construct on the T cells, or its inability to generate a sufficiently sustained response.
Since there are differences in the design of different players’ CAR constructs it is hoped that further data will shed light on which of these differences might affect persistence. For instance, Kite employs a gamma-retrovirus to transfect its construct, which uses a CD28 co-stimulatory domain, while Novartis ’s uses lentiviral transfection and a 4-1BB co-stimulatory element.
Juno has both: JCAR015 , a CD28 /gamma-retroviral construct from Memorial Sloan Kettering (MSK ), and JCAR017 , a 4-1BB/lentiviral one from the Fred Hutchinson Cancer Research Center . Again there is a lack of hard evidence, but Dr Grupp of the Philadelphia children's hospital says his construct, which is used by Novartis , enables persistence of around four years, versus around 30 days for the MSK /Kite projects.
During a recent investor call Dr Grupp stated that CD28 co-stimulation tends to give a strong early response but the T cells then “burn out”, while gamma-retroviruses are known to risk causing gene silencing.
“Solely based on the data that’s published right now, I’d say there’s more compelling data that CD28 versus 4-1BB is a bigger part of the [persistence] equation than lentiviral versus gamma-retroviral,” he speculated. “But that is just a guess.”
If further trials do substantiate this view then Kite especially will be left with some rethinking to do.
费城儿童医院的Shannon Maude,说道:一位缓解期的患者对鼠源的CTL019没有反应,这是非常让人印象深刻的一件事情。这是在早期的一个研究,但是进一步在大数据病人身上得到的数据会让诺华公司非常为难:CTL109治疗组会失败,或者它只是CTL119的开关?
对于其他公司开发人源化的CARs的计划,我们所知甚少。Kite公司已经申请了一个专利,Juno公司由于其研究与发展部门的带头人Mark Frohlich的研究而获得红利,该公司第一次在临床试验中的病人身上使用了完全人源化的CAR-T细胞产品。
CD19 阳性或者抗原逃逸?
在最近的诺华公司的CTL019治疗ALL病人的试验中,在治疗一个月后,出现了令人印象深刻的93%的完全缓解率,虽然1年后,这个完全缓解率下降到30%。在ASH年会上,费城儿童医院的Stephan Grupp先生提到,CD19阳性导致的逃逸这个原因占到了疾病复发的1/3 。(12月8日, 2015)
在这个领域中,占主导地位的是JCAR018,一个靶向CD22的CAR,它来源于NIH,在去年被Juno花了12000万从Opus Bio公司买下。一个单独的ASH海报上详细报道了JCAR018的第一个人体试验,包含七个ALL病人,其中的6个患者曾经接受CD19 CAR的治疗,其中有5个病人曾经出现过CD19缺失导致的逃逸。
CAR-T细胞治疗基于对抗原的选择,它的发展趋向于跟随抗原的发展,CD22也不例外。但有趣的是靶向CD22的单克隆抗体,包括MEDI-553和IMTOX 22-97,在癌症的治疗中都已失败,就像优时比公司的epratuzumab在狼疮治疗中也失败了。
在ASH年会上NCI的Daniel Lee先生提到,他给予CD19逃逸的病人进行CD22CAR-T技术治疗,从这个试验中得到的数据很有可能是属于Iuno公司,而不是NCI的合作研究和发展合约伙伴Kite公司。
当出现了CD19阳性导致的逃逸, CAR-T技术的研究者不得不面对一个问题,即T细胞上CAR的结构缺乏持续性,或者不能够产生足够的持续性的有效性。

您需要登录后才可以回帖 登录 | 注册


QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-1-17 10:51 , Processed in 0.108084 second(s), 24 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表